Phenotypic cyclophosphamide resistance in mouse myeloma hybridomas.

Abstract

We have analyzed the expression of cyclophosphamide (CY) resistance in somatic cell hybrids of mouse LPC-1/CY-R plasmacytoma and P3-X63-Ag8.653 (Ag8) myeloma cells. LPC-1/CY-R tumor is resistant to curative doses (60-250 mg/kg body weight) of CY. The median survival time (MST) of drug treated LPC-1/CY-R tumor bearing mice is 25 days, similar to that of untreated mice. LPC-1/CY-R tumor cells secrete an IgG 2a kappa M component and do not survive in tissue culture. Ag8 tumor cells are CY sensitive, are selected out in hypoxanthine-aminopterin-thymidine (HAT) media and do not secrete any immunoglobulin. Hybrids formed between these two cell lines survived in HAT and secreted IgG 2a kappa. Hybrid cells exhibited greater ploidy than that of their parents and contained the metacentric marker chromosome of the Ag8 cell line. Hybrid cells exhibited the same growth characteristics in BALB/c mice as that of their LPC-1/CY-R parent and were resistant to curative doses of CY. These studies demonstrate that, CY resistance is a somatic cell dominant trait which can be transferred to daughter cells via somatic cell hybridization. Availability of somatic cell hybrids produced between CY sensitive and resistant tumor cells may provide useful tools to study the biochemical nature and the somatic cell genetics of this drug resistant trait.

• Authors: C G Frondoza, J P DiSanto, R L Humphrey
• Journal: Hybridoma (Hybridoma) Vol. 7 Issue 4 Pg. 397-405 (Aug 1988) ISSN: 0272-457X [Print] United States
• PMID: 3169807 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Immunoglobulins
• Cyclophosphamide

Topics

• Animals
• Cyclophosphamide (pharmacology)
• Drug Resistance (genetics)
• Female
• Hybridomas (drug effects)
• Immunoglobulins (biosynthesis)
• Mice
• Mice, Inbred BALB C
• Neoplasm Transplantation
• Plasmacytoma (drug therapy, genetics)